Literature DB >> 15370156

Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials.

Saul Shiffman1, Robert West, David Gilbert.   

Abstract

This paper addresses methodological issues in the assessment of nicotine withdrawal and craving in clinical trials of smoking cessation therapies. We define withdrawal as a syndrome of behavioral, affective, cognitive, and physiological symptoms, typically transient, emerging upon cessation or reduction of tobacco use and causing distress or impairment of behavioral function. Offset effects (effects related to removal of a direct nicotine effect) are sustained effects of cessation or reduction of tobacco use that cause distress or impairment. Withdrawal and craving are important as potential predictors of relapse, as mediators and markers of treatment effects, and as clinical phenomena in their own right. Symptoms recommended for assessment include craving, irritability, depression, restlessness, sleep disturbance, difficulty concentrating, increased appetite, and weight gain; anxiety deserves further study. We recommend reporting of data on each of these individual symptoms, and use of multiple-item assessments. Although some standardized measures of withdrawal have promising psychometric properties, no measure has yet fully established its reliability, validity, and broad applicability and, therefore, we do not currently favor universal adoption of any one measure. Assessment of objective indices of withdrawal (e.g., hormonal changes) is currently technically challenging and of unknown value. Although weekly assessment may suffice in some large trials, more intensive measurement can provide better sensitivity. Analyses of withdrawal should include baseline measures and be sensitive to potential instability in baseline. Analytic approaches should take into account potential bias when only abstinent subjects are examined. Conversely, heterogeneity should be considered when smoking subjects are included in intent-to-treat analyses. Withdrawal data from clinical trials focused on assessing abstinence rates may be biased because of progressive subject loss to dropout and relapse; different designs and approaches are needed to investigate the process and natural history of craving and withdrawal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15370156     DOI: 10.1080/14622200410001734067

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  90 in total

1.  Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal.

Authors:  Robert West; Peter Hajek
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

2.  The early time course of smoking withdrawal effects.

Authors:  Peter S Hendricks; Joseph W Ditre; David J Drobes; Thomas H Brandon
Journal:  Psychopharmacology (Berl)       Date:  2006-06-03       Impact factor: 4.530

3.  Acute effects of self-paced walking on urges to smoke during temporary smoking abstinence.

Authors:  Adrian H Taylor; Magdalena Katomeri; Michael Ussher
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

4.  Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h.

Authors:  Vincenzo Teneggi; Stephen T Tiffany; Lisa Squassante; Stefano Milleri; Luigi Ziviani; Alan Bye
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

5.  Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study.

Authors:  Sean P David; Marcus R Munafò; Heidi Johansen-Berg; Stephen M Smith; Robert D Rogers; Paul M Matthews; Robert T Walton
Journal:  Biol Psychiatry       Date:  2005-07-14       Impact factor: 13.382

Review 6.  Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies.

Authors:  Mark G LeSage; Daniel E Keyler; Paul R Pentel
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

7.  The relationship between level of cigarette consumption and latency to the onset of retrospectively reported withdrawal symptoms.

Authors:  W W S A Fernando; Robert J Wellman; Joseph R Difranza
Journal:  Psychopharmacology (Berl)       Date:  2006-09-05       Impact factor: 4.530

8.  Effects of acute tobacco abstinence in adolescent smokers compared with nonsmokers.

Authors:  Anne E Smith; Dana A Cavallo; Tricia Dahl; Ran Wu; Tony P George; Suchitra Krishnan-Sarin
Journal:  J Adolesc Health       Date:  2008-03-06       Impact factor: 5.012

Review 9.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

10.  Intra-individual changes in Stroop-related activations linked to cigarette abstinence in adolescent tobacco smokers: Preliminary findings.

Authors:  Sarah W Yip; Iris M Balodis; Kathleen M Carroll; Suchitra Krishnan-Sarin; Marc N Potenza
Journal:  Drug Alcohol Depend       Date:  2016-08-21       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.